Research
Molecular
Dapagliflozin lowers blood glucose independent of insulin secretion and action.
Dapagliflozin can be used to manage blood glucose levels without relying on insulin.
StrongSupportsmedium confidence
Dapagliflozin lowers blood glucose independent of insulin secretion and action by inhibiting renal reabsorption of glucose.
Why this rating
The claim is based on clinical efficacy data from trials.
Source
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva Vivian · American Journal of Health-System Pharmacy · 2015
DOI 10.2146/ajhp140168
reviewCited 44×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →